- Home
- GCI vs STOK Comparison
GCI vs STOK Comparison
Compare GCI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- STOK
- Stock Information
- Founded
- GCI 1997
- STOK 2014
- Country
- GCI United States
- STOK United States
- Employees
- GCI N/A
- STOK N/A
- Industry
- GCI Newspapers/Magazines
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- STOK Health Care
- Exchange
- GCI Nasdaq
- STOK Nasdaq
- Market Cap
- GCI 854.6M
- STOK 721.4M
- IPO Year
- GCI N/A
- STOK 2019
- Fundamental
- Price
- GCI $5.38
- STOK $11.43
- Analyst Decision
- GCI Buy
- STOK Strong Buy
- Analyst Count
- GCI 3
- STOK 7
- Target Price
- GCI $5.37
- STOK $21.40
- AVG Volume (30 Days)
- GCI 1.5M
- STOK 461.9K
- Earning Date
- GCI 10-31-2024
- STOK 11-05-2024
- Dividend Yield
- GCI N/A
- STOK N/A
- EPS Growth
- GCI N/A
- STOK N/A
- EPS
- GCI N/A
- STOK N/A
- Revenue
- GCI $2,557,445,000.00
- STOK $16,742,999.00
- Revenue This Year
- GCI N/A
- STOK $91.67
- Revenue Next Year
- GCI N/A
- STOK $5.45
- P/E Ratio
- GCI N/A
- STOK N/A
- Revenue Growth
- GCI N/A
- STOK 81.08
- 52 Week Low
- GCI $1.83
- STOK $3.77
- 52 Week High
- GCI $5.93
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- GCI 53.30
- STOK 36.03
- Support Level
- GCI $4.83
- STOK $11.08
- Resistance Level
- GCI $5.80
- STOK $11.73
- Average True Range (ATR)
- GCI 0.23
- STOK 0.73
- MACD
- GCI -0.00
- STOK -0.23
- Stochastic Oscillator
- GCI 58.42
- STOK 9.62
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.